Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
NCT03652441
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
14
Enrollment
OTHER
Sponsor class
Conditions
Classical Hodgkin Lymphoma
Interventions
DRUG:
Brentuximab Vedotin
Sponsor
University of Cologne